HuGE Literature Finder
Records
1
-
6
Analysis of matched primary and recurrent BRCA1/2 mutation-associated tumors identifies recurrence-specific drivers. Nature communications 2022 11 13 (1): 6728. Shah Jennifer B, Pueschl Dana, Wubbenhorst Bradley, Fan Mengyao, Pluta John, D'Andrea Kurt, Hubert Anna P, Shilan Jake S, Zhou Wenting, Kraya Adam A, Llop Guevara Alba, Ruan Catherine, Serra Violeta, Balmaña Judith, Feldman Michael, Morin Pat J, Nayak Anupma, Maxwell Kara N, Domchek Susan M, Nathanson Katherine |
Association between the PARP1 Val762Ala polymorphism and cancer risk: evidence from 43 studies. PloS one 2014 9 (1): e87057. Hua Rui-Xi, Li He-Ping, Liang Yan-Bing, Zhu Jin-Hong, Zhang Bing, Ye Sheng, Dai Qiang-Sheng, Xiong Shi-Qiu, Gu Yong, Sun Xiang-Zh |
Association of poly(ADP-ribose) polymerase-1 polymorphism with Tourette syndrome. Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology 2013 Nov 34 (11): 1911-6. Wu Bor-Tsang, Lin Wei-Yong, Chou I-Ching, Liu Hsin-Ping, Lee Cheng-Chun, Tsai Yuhsin, Lee Jia-Ye, Tsai Fuu-J |
Association analysis of PARP1 polymorphisms with Parkinson's disease. Parkinsonism & related disorders 2011 Nov 17 (9): 701-4. Brighina Laura, Riva Chiara, Bertola Francesca, Fermi Silvia, Saracchi Enrico, Piolti Roberto, Goldwurm Stefano, Pezzoli Gianni, Ferrarese Car |
Analysis of poly(ADP-ribose) polymerase-1 (PARP1) gene alteration in human germ cell tumor cell lines. Cancer genetics and cytogenetics 2010 Feb 197 (1): 8-15. Ogino Hideki, Nakayama Robert, Sakamoto Hiromi, Yoshida Teruhiko, Sugimura Takashi, Masutani Mitsu |
Leu54Phe and Val762Ala polymorphisms in the poly(ADP-ribose)polymerase-1 gene are associated with diabetic polyneuropathy in Russian type 1 diabetic patients. Diabetes research and clinical practice 2008 Mar 79 (3): 446-52. Nikitin Alexey G, Chudakova Dariya A, Strokov Igor A, Bursa Tamara R, Chistiakov Dimitry A, Nosikov Valery |
- Page last reviewed:Feb 1, 2023
- Page last updated:Mar 28, 2023
- Content source: